With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium

Vandana Singh
1 min read
0
In this article:

  • Cantor Fitzgerald initiated coverage on Actinium Pharmaceuticals Inc (NYSE: ATNM) with an Overweight rating and a price target of $20, almost an upside of 145%.

  • Actinium is a clinical-stage biopharmaceutical company that is currently developing oncology therapies.

  • This includes the lead program, IomabB, a targeted conditioning therapy administered in preparation for a bone marrow transplant (BMT), adoptive cell therapy (ACT), and Actimab-B, combined with other therapeutic therapy agents.

  • Related: Actinium's Targeted Radiotherapy Achieves 100% Bone Marrow Transplant Engraftment.

  • The analyst believes that the SIERRA trial is the only randomized Phase 3 study that offers BMT as a treatment option for patients with active r/r Acute Myeloid Leukemia (AML).

  • "We think it is essential to focus on a "Goldilocks" approach in finding a dose/regimen that balances safety and efficacy," the analyst writes.

  • The potential expansion of Iomab-B may also go beyond CD45 space, considering conditioning remains an integral part of adoptive cell therapies.

  • "Actinium has already achieved proof of concept in some of these settings. We think this could dramatically expand the market opportunity and open the door for further partnerships." Cantor writes.

  • Price Action: ATNM shares are up 9.59% at $8.23 on the last check Thursday.

Latest Ratings for ATNM

Date

Firm

Action

From

To

Aug 2021

HC Wainwright & Co.

Maintains

Buy

Apr 2021

HC Wainwright & Co.

Maintains

Buy

Jun 2020

HC Wainwright & Co.

Initiates Coverage On

Buy

View More Analyst Ratings for ATNM

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories